Education
About Us
Working with TipRanks
Follow Us
Argenx (DE:1AEA)
:1AEA
1AEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€322.00 - €660.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€32.28B
Enterprise ValueN/A
Total Cash (Recent Filing)$321.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)48.3
Beta-0.12
Next Earnings
May 08, 2025EPS Estimate
2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.81
Shares Outstanding60,760,956
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)86.46
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€687.86Price Target Upside20.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionApproval of the PFS with self-administration is expected to expand prescriber bases and patient networks, enhancing Vyvgart's momentum.
Regulatory ApprovalsUpcoming regulatory catalysts that could support additional Vyvgart growth include the potential approval of pre-filled syringes for CIDP in Europe and for gMG and CIDP in Japan and Canada.
Bears Say
Discontinued DevelopmentsARGX is discontinuing development of Vyvgart in BP based on results from the Ph.2 BALLAD study.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
19.91% Mutual Funds
8.09% Other Institutional Investors
70.61% Public Companies and Individual Investors
1AEA FAQ
What was Argenx’s price range in the past 12 months?
Argenx lowest stock price was €322.00 and its highest was €660.00 in the past 12 months.
What is Argenx’s market cap?
Argenx’s market cap is €32.28B.
When is Argenx’s upcoming earnings report date?
Argenx’s upcoming earnings report date is May 08, 2025 which is in 57 days.
How were Argenx’s earnings last quarter?
Argenx released its earnings results on Oct 31, 2024. The company reported €1.327 earnings per share for the quarter, beating the consensus estimate of €0.14 by €1.186.
Is Argenx overvalued?
According to Wall Street analysts Argenx’s price is currently Undervalued.
Does Argenx pay dividends?
Argenx does not currently pay dividends.
What is Argenx’s EPS estimate?
Argenx’s EPS estimate is 2.2.
How many shares outstanding does Argenx have?
Argenx has 60,760,956 shares outstanding.
What happened to Argenx’s price movement after its last earnings report?
Argenx reported an EPS of €1.327 in its last earnings report, beating expectations of €0.14. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argenx?
Currently, no hedge funds are holding shares in DE:1AEA
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€687.86 (20.68% Upside)
€687.86 (20.68% Upside)
Blogger Sentiment
Bullish
DE:1AEA Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.24%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
1AEA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical milestones, financial growth, and pipeline expansion, indicating strong momentum. However, there were challenges with exchange losses and an operating loss despite revenue growth. Overall, the positive aspects and future outlook outweigh the negatives.Read More>---
1AEA Stock 12 Month Forecast
Average Price Target
€687.86
▲(20.68% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering 1AEA
1 Year
1 Year Success Rate
21/24 ratings generated profit
1 Year Average Return
+44.65%
reiterated a buy rating 14 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +44.65% per trade.
---